Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with olaparib an inhibitor of the PARP enzyme (PARPi).

Trial Details

NCT ID
NCT03150576
Phase
PHASE2 / PHASE3
Sponsor
Cambridge University Hospitals NHS Foundation Trust
Status
RECRUITING
Cancer Type
Ductal Carcinoma In Situ (DCIS) Breast Cancer
Interventions
  • Olaparib
  • Paclitaxel and Carboplatin
Locations (sample)
  • Cambridge, Cambridgeshire, United Kingdom|52.2,0.11667
  • Burton-on-Trent, Derby, United Kingdom|52.80728,-1.64263
  • Manchester, Lancs, United Kingdom|53.48095,-2.23743
  • Wakefield, Yorkshire, United Kingdom|53.68331,-1.49768
  • Ayr, United Kingdom|55.46273,-4.63393

Key Eligibility Criteria

  • Aged between 16 and 70.
  • Written informed consent, willing and able to comply with the Protocol for the duration of the trial including undergoing treatment and scheduled v…
  • Histologically confirmed invasive breast cancer.
  • ER-negative\*, and HER2-negative\*\* breast cancer (TNBC). Patients will be eligible with any PR status but PR expression must be scored.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ductal Carcinoma In Situ (DCIS) Breast Cancer Trials on Trialify →